- Home
- CING vs TXMD Comparison
CING vs TXMD Comparison
Compare CING & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- TXMD
- Stock Information
- Founded
- CING 2012
- TXMD 2008
- Country
- CING United States
- TXMD United States
- Employees
- CING N/A
- TXMD N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- TXMD Health Care
- Exchange
- CING Nasdaq
- TXMD Nasdaq
- Market Cap
- CING 16.2M
- TXMD 17.1M
- IPO Year
- CING 2021
- TXMD N/A
- Fundamental
- Price
- CING $4.36
- TXMD $1.25
- Analyst Decision
- CING Strong Buy
- TXMD
- Analyst Count
- CING 4
- TXMD 0
- Target Price
- CING $30.67
- TXMD N/A
- AVG Volume (30 Days)
- CING 250.6K
- TXMD 60.7K
- Earning Date
- CING 05-08-2025
- TXMD 05-13-2025
- Dividend Yield
- CING N/A
- TXMD N/A
- EPS Growth
- CING N/A
- TXMD N/A
- EPS
- CING N/A
- TXMD N/A
- Revenue
- CING N/A
- TXMD $1,841,000.00
- Revenue This Year
- CING N/A
- TXMD $427.09
- Revenue Next Year
- CING N/A
- TXMD N/A
- P/E Ratio
- CING N/A
- TXMD N/A
- Revenue Growth
- CING N/A
- TXMD 53.55
- 52 Week Low
- CING $1.80
- TXMD $0.70
- 52 Week High
- CING $20.83
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- CING 61.94
- TXMD 46.57
- Support Level
- CING $3.81
- TXMD $1.00
- Resistance Level
- CING $4.09
- TXMD $1.51
- Average True Range (ATR)
- CING 0.26
- TXMD 0.11
- MACD
- CING 0.07
- TXMD -0.05
- Stochastic Oscillator
- CING 96.43
- TXMD 47.17
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.